ABX 196
Alternative Names: ABX-196Latest Information Update: 28 Apr 2023
At a glance
- Originator Brigham Young University; The Scripps Research Institute; University of Chicago
- Developer Abivax
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Immunostimulants; Natural killer T cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Liver cancer
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for phase-I development in Liver-cancer(In volunteers) in France (IM, Injection)
- 26 Aug 2021 ABX 196 is available for licensing as of 26 Aug 2021. https://www.abivax.com/pipeline/abx196/ (Abivax pipeline, August 2021)